Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016

Authors:
Publisher website
Google Scholar
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent, affecting approximately 20 million people in the US.1,2 Statin therapy is a pillar of secondary prevention for these patients,3 but numerous studies showed a substantial rate of nonadherence and undertreatment.4,5 The benefits of adhering to statin therapy have been reported.6-8 The past decade has witnessed extensive efforts and innovative interventions to improve statin adherence, however with varying degrees of success.9 The 2013 American College of Cardiology/American Heart Association (ACC/AHA) recommended high-intensity statins for all patients age 75 years and younger with documented ASCVD in whom such therapy is tolerated,10 and generic high-intensity statins have become widely available.

This publication has 41 references indexed in Scilit: